Nov 14, 2025, 08:54 AM by

BioGrad is spearheading efforts to place £10.5 million worth of donated PCR equipment by the end of 2025, with £6 million already delivered across the UK.

Nov 14, 2025, 01:00 AM by User Not Found

Bio-IT World | Early computational drug discovery relies on accurate predictions of binding affinity. If we can accurately predict the affinity of molecule designs, we can dramatically reduce the number of compounds that we need to synthesize and test when optimizing new drug candidates.

Nov 13, 2025, 08:15 AM by

ThirdLaw Molecular, Inc. today announced its new name change, Ladder Bio Inc., reflecting the company’s mission to pioneer Spiroligomer™ therapeutics (“ladder-shaped peptide-like molecules”), a novel therapeutic modality for new medicines. The company name change follows the closing of a $5.5 million Series Seed financing led by Medical Excellence Capital, with participation from Hatch BioFund. The company also announced the appointment of Eric Heil as Chief Executive Officer and the election of David Scheer and Brian Halak, PhD to its Board of Directors.

Nov 13, 2025, 08:15 AM by

IgniteData’s Archer platform will connect the site’s EHR system, Advarra’s eSource and EDC systems, and the sponsor’s EDC system of choice, ensuring compatibility between solutions from different vendors.

Nov 13, 2025, 08:15 AM by

Collaboration aims to equip users with complete NGS solution from sample to answer

Nov 12, 2025, 07:44 AM by

CluePoints, provider of leading statistical and AI-driven software solutions, has announced Sylviane de Viron, its Data and Knowledge Manager, has been appointed to the Applied Clinical Trials (ACT) editorial advisory board.

Nov 12, 2025, 01:01 AM by User Not Found

Bio-IT World | Though gender equity efforts in research have made strides, progress has plateaued. Roughly two-thirds of pivotal clinical trials leading to the U.S. Food and Drug Administration (FDA) drug approvals now include women at rates proportional to their disease burden, but the problem is fundamental issues in not considering female biology.

Nov 12, 2025, 01:00 AM by User Not Found

Bio-IT World | Though gender equity efforts in research have made strides, progress has plateaued. Roughly two-thirds of pivotal clinical trials leading to the U.S. Food and Drug Administration (FDA) drug approvals now include women at rates proportional to their disease burden, but the problem is fundamental issues in not considering female biology.

Nov 11, 2025, 08:11 AM by

* Ready-to-use solution, developed in collaboration with GenScript, offers rapid and reliable quantification of His-tagged proteins * Broadens Amperia’s applications across recombinant protein research, screening, and development * Abselion to showcase kit alongside Amperia platform at PEGS Europe in Lisbon, Portugal from 11–13 November

Nov 11, 2025, 08:11 AM by

MadeAi launched new capabilities in its MadeAi(TM) GenAI-powered platform for life science evidence synthesis and report generation - capabilities that expedite global value dossier (GVD) and Joint Clinical Assessment (JCA), and streamline literature review from protocol creation to regulatory-ready reporting.

Nov 11, 2025, 01:01 AM by User Not Found

Bio-IT World | Watchmaker Genomics has launched TAPS+, a next-generation technology that unites genetic and epigenetic readouts from the same DNA molecule. By capturing multiple biological dimensions in a single assay, TAPS+ delivers a richer, more comprehensive view of tumor biology.

Nov 6, 2025, 10:06 AM by User Not Found

Bio-IT World | Antibody-drug conjugates (ADCs) are among the most promising and complex therapeutics in modern oncology. The global ADC market is growing at an extraordinary pace. Yet, this promise comes with complexity. Multi-step conjugations, long processing times, highly potent raw materials, and stringent quality requirements pose significant manufacturing challenges.

Nov 6, 2025, 07:55 AM by

Nov 6, 2025, 07:55 AM by

Nov 5, 2025, 01:00 AM by User Not Found

Bio-IT World | For millions of patients prescribed drugs with a narrow therapeutic window, safe dosing depends on therapeutic drug monitoring. But outside of hospital labs equipped with specialized machines and trained staff, monitoring drug concentrations in real time has been largely out of reach. DNA nanotechnology may hold the key to bringing this critical capability to the point of care—and even into patients’ homes.

Nov 4, 2025, 08:47 AM by

Partnership with Solve Scientific strengthens international sales as part of ongoing global expansion

Nov 4, 2025, 08:47 AM by

DoseMe, a global leader in model-informed precision dosing (MIPD) software and a portfolio company of Fairlong Capital, today announced the acquisition of Firstline, a leading clinical decision support platform utilized worldwide. Firstline enables clinicians to rapidly access local, evidence-based infectious disease treatment guidance, susceptibility patterns, and antimicrobial stewardship (AMS) resources. The combination of DoseMe and Firstline creates a single, connected experience from therapy selection through personalized dosing, giving clinicians a faster path to optimal care.

Nov 4, 2025, 08:46 AM by

Nov 4, 2025, 01:01 AM by User Not Found

Bio-IT World | Pacific Biosciences announced a chemistry upgrade and SMRT cell reuse capability last month at the American Society of Human Genetics (ASHG) meeting. CEO Christian Henry said the moves targeted dramatic price reductions for customers and to compete with short-read sequencing.

Nov 3, 2025, 08:52 AM by

Lonza has announced that it has signed an agreement to acquire Redberry.